ACUITI

This study assessed the feasibility and performance of a tumor-informed circulating tumor DNA (ctDNA) assay in patients with metastatic HR+/HER2- breast cancer receiving endocrine therapy and CDK4/6 inhibitors.

Type: Exome Sequencing
Archiver: European Genome-Phenome Archive (EGA)

1 Dataset 1 Publication

Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data

Dataset ID	Description	Technology	Samples
EGAD50000001401	This dataset contains WES bam/bai files associated with 51 patients as part of the ACUITI Study	Illumina NovaSeq 6000	51

Publications	Citations
Personalized ctDNA monitoring in metastatic HR+/HER2- breast cancer patients during endocrine and CDK4/6 inhibitor therapy. Fuentes-Antrás J, Elliott MJ, Main SC, Echelard P, Dou A, Bedard PL, Amir E, Nadler MB, Meti N, Gregorio N, Shah E, Van de Laar E, Yu C, Deng Y, Gates L, Murray C, Smith CG, Chevalier A, Bratman SV, Siu LL, Berman HK, Cescon DW. NPJ Breast Cancer 11: 2025 74	1